How can we set the Target IOP in glaucoma patients who are progressing at unsafe rates?

It is not intuitive and needs to be individualised.

Data presented during the first two decades of this millennium has shed valuable light on how the intraocular pressure (IOP) is linked to glaucomatous progression. Large prospective controlled trials have confirmed that there is a correlation between the change in intraocular pressure (IOP) and the risk for visual field progression. The magnitude of the effect, as indicated by these studies, is a 10-15% decrease in risk for a 1 mmHg drop in IOP.

The risk is correlated to the rate at which patients develop field loss, i.e. the Rate of Progression or RoP, which in turn makes future projections of a patient’s progression over time at a given IOP level a reasonable possibility. This led to the creation of the SSY (Save Sight Years) concept and later the SSY Engine, which is a practical application of this model in the form of a web application.*

* Heijl A., Brandel M., Acta Ophthalmol. 2020 Sep 15 (epub ahead of print)

Want to learn more?

Join us for a 1-hour webcast with professor Anders Heijl. We will discuss the scientific background, how the SSY Engine works, the caveats and how it can benefit clinical practice.

Previous webcasts:
12 november 2020, kl 19.00-20:00 (GMT +1)
10 december 2020, kl 16:00-17:00 (GMT +1)
21 januari 2021 kl 19:00-20:00 (GMT +1)
New dates TBA

Want access to the SSY Engine?

    AbbVie is a research-driven biopharma company with the mission to discover and develop new innovative medicines that solve serious health issues today and tomorrow. We focus on eye care, immunology, oncology, neuroscience, virology and the Allergan Aesthetics portfolio. In Scandinavia, we are about 330 employees with offices in Stockholm, Oslo and Copenhagen. All three countries are ranked as a top employer by Great Place to Work.

    SSY Engine is a guidance tool for HCPs and should not be used as a substitute for medical knowledge and experience. Developed, registered and distributed by Careful Apps under a license by Allergan. Besides the cloud-based web version, it is available as an app for iPads and Android tablets. Date of preparation: ND-NON-2050025 October 2020